New Data Positions Tazbentetol as Potential Game-Changer for Vision Preservation, Spinogenix Tells ARVO 2026
Experimental therapy targets neural repair to combat blindness from glaucoma and diabetic retinopathy
LOS ANGELES — Spinogenix is spotlighting new preclinical findings that could reshape how vision-threatening diseases are treated, as its experimental drug tazbentetol (SPG302) demonstrates the ability to protect and restore retinal function. The results are being presented at the Association for Research in Vision and Ophthalmology Annual Meeting.
The research places emphasis on a growing scientific consensus: that repairing neural damage in the eye may be just as critical as controlling the underlying disease itself.
Rethinking the Fight Against Blindness
Globally, glaucoma and diabetic retinopathy continue to rank among the leading causes of irreversible blindness. Traditional treatment strategies largely focus on slowing disease progression by managing risk factors such as eye pressure or blood sugar.
However, scientists are increasingly recognising that early loss of synaptic connections in the retina plays a central role in vision decline. Once these neural links are disrupted, the ability of the eye to transmit visual signals deteriorates rapidly.
Tazbentetol seeks to address this gap by promoting synaptic regeneration, offering a fundamentally different approach aimed at preserving the eye’s neural circuitry.
Robust Neuroprotection Observed in Preclinical Testing
To evaluate its effectiveness, researchers conducted studies using two disease-relevant mouse models. One model artificially induced glaucoma through elevated intraocular pressure, while the other simulated diabetes-related retinal damage using genetically diabetic mice.
Across both models, animals treated with tazbentetol over eight weeks exhibited strong neuroprotective outcomes. Retinal ganglion cells — the critical neurons responsible for relaying visual information to the brain — were preserved, in contrast to significant degeneration observed in untreated groups.
The treatment also maintained synaptic integrity and protected the optic nerve, suggesting a broad protective effect across multiple components of the visual pathway.
Functional Gains Reinforce Structural Findings
The benefits extended beyond cellular preservation. Functional testing revealed measurable improvements in visual performance, reinforcing the biological data.
Indicators such as pattern electroretinography (pERG) showed restored retinal activity, while diabetic models demonstrated faster neural signal transmission, evidenced by improved visual evoked responses.
These results indicate that the therapy not only prevents structural damage but may also restore the efficiency of visual processing.
A Step Toward Transformative Eye Care
The implications of these findings extend beyond ophthalmology. By targeting synaptic repair, tazbentetol introduces a therapeutic concept that could influence treatment strategies for a range of neurodegenerative disorders.
Although still in the experimental stage, the data presented at ARVO 2026 strengthens the case for advancing synaptic regenerative therapies into clinical development, offering renewed hope for patients at risk of losing their vision.
-wilayah.com.my
